title: Hemodynamic and endocrine responses to guanfacine in normotensive volunteers and hypertensive patients.
abstract: The centrally acting alphamimetic antihypertensive drug, guanfacine, was studied in normotensive volunteers and patients with essential and renal hypertension. After acute (0.02 mg/kg, intravenously) and short-term (mean dose: 6.7 mg/day orally for 4 weeks) administration of guanfacine, systolic, diastolic and mean blood pressures (BPs), heart rate, cardiac output and right atrial pressure were measured by standard techniques. Cardiac index, stroke volume and total peripheral vascular resistance were calculated. After medium-term therapy (mean dose: 6 mg/day orally for 12 weeks), antihypertensive efficacy, as well as plasma renin activity and catecholamine levels, was determined. After intravenous administration, guanfacine lowered systolic, diastolic and mean arterial BPs after a brief and transient increase. Guanfacine exerted its antihypertensive action primarily by its effect on total peripheral resistance. Reflex tachycardia was not observed. Heart rate was reduced. Stroke volume increased and right atrial pressure decreased. These effects were maintained or enhanced during the 4 weeks of oral therapy that followed. In the 12-week study, significant reductions in systolic, diastolic and mean BPs were observed. With a constant dose of 3 mg/day for 1 week, BP decreased from 197/115/149 (systolic/diastolic/mean) to 166/97/126 mm Hg. After 4 weeks at varying doses, BP decreased to 157/91/118, and after 12 weeks, to 147/83/109. In the 12 patients treated for 4 weeks with 3 mg/day, a significant decrease from 192/111/145 to 151/87/114 mm Hg was observed, while in the 6 patients treated for 12 weeks with the 3 mg/day dose, the final readings showed a decrease of 50 mm Hg in systolic pressure, 30 mm Hg in diastolic pressure and 38.4 mm Hg in mean arterial pressure.(ABSTRACT TRUNCATED AT 250 WORDS)
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D004341:Drug Evaluation; D005260:Female; D016316:Guanfacine; D006146:Guanidines / Q000627:therapeutic use*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D006977:Hypertension, Renal / Q000188:drug therapy*; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D010648:Phenylacetates / Q000627:therapeutic use*; D012083:Renin / Q000097:blood; D013318:Stroke Volume / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D006146:Guanidines; D010648:Phenylacetates; D016316:Guanfacine; D012083:Renin; D009638:Norepinephrine